pharmacological management of parkinsons disease
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Begum, Borsa Marofa | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2021-06-16T11:25:55Z | |
| dc.date.available | 2021-06-16T11:25:55Z | |
| dc.date.created | 2020 | |
| dc.description.abstract | During the past decades many different new therapy strategies for the treatment of Parkinson’s disease have been developed. There is no cure for Parkinson’s disease. The main aim with pharmacotherapy is to treat the symptoms to provide temporary relief from symptoms to maintain a quality of life in patients with Parkinson’s disease. But do not stop or slow the underlying neurodegenerative process. We discuss the variety of possible options to help control the symptoms and the side effects of these drugs to improve the patient’s quality of life. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 35 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/311170 | |
| dc.language.iso | en | hu_HU |
| dc.subject | parkinsons disease | hu_HU |
| dc.subject | levodopa | |
| dc.subject | deep brain stimulation | |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | pharmacological management of parkinsons disease | hu_HU |